You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHypoxanthine
Accession NumberDB04076  (EXPT01767)
Typesmall molecule
Groupsexperimental
Description

A purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway. [PubChem]

Structure
Thumb
SynonymsNot Available
SaltsNot Available
Brand namesNot Available
Brand mixturesNot Available
CategoriesNot Available
CAS number68-94-0
WeightAverage: 135.1035
Monoisotopic: 135.030685738
Chemical FormulaC5H3N4O
InChI KeyCWQZZPRFMBHEEG-UHFFFAOYSA-N
InChI
InChI=1S/C5H3N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H,7,8,9,10)
IUPAC Name
purin-6-one
SMILES
O=C1NC=Nc2ncnc12
Mass SpecNot Available
Taxonomy
KingdomNot Available
SuperclassNot Available
ClassNot Available
SubclassNot Available
Direct parentNot Available
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Azathioprine Action PathwayDrug actionSMP00427
Thioguanine Action PathwayDrug actionSMP00430
Mercaptopurine Action PathwayDrug actionSMP00428
Adenine phosphoribosyltransferase deficiency (APRT)DiseaseSMP00535
Adenosine Deaminase DeficiencyDiseaseSMP00144
Adenylosuccinate Lyase DeficiencyDiseaseSMP00167
AICA-RibosiduriaDiseaseSMP00168
Molybdenium Cofactor DeficiencyDiseaseSMP00203
Myoadenylate deaminase deficiencyDiseaseSMP00537
Xanthine Dehydrogenase Deficiency (Xanthinuria)DiseaseSMP00220
Purine Nucleoside Phosphorylase DeficiencyDiseaseSMP00210
Mitochondrial DNA depletion syndromeDiseaseSMP00536
Gout or Kelley-Seegmiller SyndromeDiseaseSMP00365
Xanthinuria type IDiseaseSMP00512
Xanthinuria type IIDiseaseSMP00513
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Purine MetabolismMetabolicSMP00050
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9948
Blood Brain Barrier + 0.9758
Caco-2 permeable - 0.7161
P-glycoprotein substrate Non-substrate 0.6693
P-glycoprotein inhibitor I Non-inhibitor 0.9462
P-glycoprotein inhibitor II Non-inhibitor 0.9626
Renal organic cation transporter Non-inhibitor 0.8869
CYP450 2C9 substrate Non-substrate 0.8095
CYP450 2D6 substrate Non-substrate 0.7824
CYP450 3A4 substrate Non-substrate 0.6692
CYP450 1A2 substrate Inhibitor 0.6493
CYP450 2C9 substrate Non-inhibitor 0.913
CYP450 2D6 substrate Non-inhibitor 0.9212
CYP450 2C19 substrate Non-inhibitor 0.8549
CYP450 3A4 substrate Non-inhibitor 0.9202
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8962
Ames test Non AMES toxic 0.6541
Carcinogenicity Non-carcinogens 0.9686
Biodegradation Not ready biodegradable 0.8452
Rat acute toxicity 2.1622 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9781
hERG inhibition (predictor II) Non-inhibitor 0.9305
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point150 dec °CPhysProp
water solubility700 mg/L (at 23 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-1.11HANSCH,C ET AL. (1995)
logS-2.29ADME Research, USCD
Predicted Properties
PropertyValueSource
water solubility3.94e+00 g/lALOGPS
logP-1.1ALOGPS
logP-1ChemAxon
logS-1.5ALOGPS
pKa (strongest acidic)7.31ChemAxon
pKa (strongest basic)-3.1ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count4ChemAxon
hydrogen donor count1ChemAxon
polar surface area71.53ChemAxon
rotatable bond count0ChemAxon
refractivity33.07ChemAxon
polarizability11.43ChemAxon
number of rings2ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Alvin J. Glasky, Heinrich Bollinger, Hans Rudolf Muller, “Methods of synthesis for 9-substituted hypoxanthine derivatives.” U.S. Patent US06849735, issued February 01, 2005.

US06849735
General ReferenceNot Available
External Links
ResourceLink
KEGG CompoundC00262
PubChem Compound790
PubChem Substance46507200
BindingDB50200102
ChEBI17368
ChEMBL
HETHPA
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available

Targets

1. Purine nucleoside phosphorylase

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Purine nucleoside phosphorylase P00491 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:23